859205-93-9Relevant academic research and scientific papers
New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases
Mastalerz, Harold,Chang, Ming,Chen, Ping,Dextraze, Pierre,Fink, Brian E.,Gavai, Ashvinikumar,Goyal, Bindu,Han, Wen-Ching,Johnson, Walter,Langley, David,Lee, Francis Y.,Marathe, Punit,Mathur, Arvind,Oppenheimer, Simone,Ruediger, Edward,Tarrant, James,Tokarski, John S.,Vite, Gregory D.,Vyas, Dolatrai M.,Wong, Henry,Wong, Tai W.,Zhang, Hongjian,Zhang, Guifen
, p. 2036 - 2042 (2007/10/03)
Novel C-5 substituted pyrrolotriazines were optimized for dual EGFR and HER2 protein tyrosine kinase inhibition. The lead compound exhibited promising oral efficacy in both EGFR and HER2 driven human tumor xenograft models. It is hypothesized that its C-5
Di-substituted pyrrolotrizine compounds
-
Page/Page column 14-15, (2010/02/13)
The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
